Comprehensive Clinical Development Finalizes Acquisition of Charles River Clinical Services

MIRAMAR, Fla.--(BUSINESS WIRE)-- Comprehensive Clinical Development, formerly operating as Comprehensive NeuroScience, Inc., a strategic clinical research organization delivering high-quality clinical development services from early proof-of-concept through commercialization, announced today the acquisition of Charles River Clinical Services Northwest, Inc., including its 250-bed, 77,000-square-foot, Phase I-IIa facility located in Tacoma, Washington.

The newly combined companies offer over 160 years of collective industry experience and provide an end-to-end “turn-key” clinical development solution, from inception of clinical testing through proof-of-concept trials. The increased capacity and capabilities deliver numerous benefits to support clients’ complete drug development programs, including:

  • Geographic diversification allowing clients a more proximal location to conduct studies and increase service offerings from coast to coast
  • Established experience in conducting radiolabeled studies
  • Streamlined optimization and extensive expertise in biologics studies
  • Access to leading physicians in numerous specialties including oncology, expansive patient populations and unique nuclear pharmacy capabilities, allowing for highly differentiated studies
  • Specialized pharmacy services optimized for compounding, including radiolabeled compounds
  • Extensive access to populations for targeting treatments for patients with Hepatitis C

Comprehensive Clinical Development CEO Jack McGovern states, "We are thrilled to have the team from Charles River Clinical Services joining the Comprehensive network. We are uniquely aligned with similar cultures, industry experience and business philosophies. What is just as exciting is how complementary the businesses are in terms of customer mix, service offerings, geographic location and subject populations.”

Charles River Clinical Services General Manager Colleen Hoke comments, “Joining Comprehensive Clinical Development is a very positive development for our future in the clinical trials industry. Leveraging best practices and the expertise of each firm will provide clear benefits to our clients. The similar cultures and aligned goals of the organizations will facilitate a smooth integration of operations.”

The President of Comprehensive Clinical Development, Ali Craig-Rodriguez added, “Having known several members of the Charles River Clinical Services management team for years, I have tremendous respect for their work. Possessing a comparable track record of organizational agility, clinical expertise, superior customer service and exceptional quality, we could not have selected a more ideal partner. Our combined capabilities will benefit our clients with a much wider array of clinical development services with the level of commitment they have always received from each company.”

About Comprehensive Clinical Development
Comprehensive Clinical Development is a strategic clinical research partner providing a full range of clinical development services in various therapeutic areas with an outstanding record for consistently delivering quality and success on time and within budget. Comprehensive Clinical Development holds a solid track record of collecting early efficacy data across various patient populations, and offers distinct capabilities in clinical research. For more information about Comprehensive Clinical Development, visit www.comprehensivecro.com.



CONTACT:

SCORR Marketing
Kelly Sladek, 308-237-5567
[email protected]

KEYWORDS:   United States  North America  Florida  Minnesota

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical  Research  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.